Novartis

Novartis is a multinational Swiss pharmaceutical company, focusing on developing and marketing innovative medicines, including prescription drugs, biosimilars, and ophthalmic products.  Every day, they work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals, and societies are empowered in the face of serious disease. Specific to neuroscience, their ambition is to create a transformational impact for people living with severe neurological conditions and their caregivers by discovering, developing, and delivering innovative medicines that change the course of disease progression.

In 2023, Novartis acquired the DTx FALCON platform and lead therapeutic candidate DTx-1252 for the treatment of CMT1A.